OncoBone Ventures is pleased to announce that it has received Advance Assurance from HMRC that investments in the Company can qualify for tax relief under the Seed Enterprise Investment Scheme (SEIS)/Enterprise Investment Scheme (EIS).

Voltron Therapeutics, Inc. has announced that data from the previously announced Study ‘098 demonstrated clear Proof-of Concept for VTX-067 in the treatment of HPV-related cancers.

CN Bio today announced the opening of new laboratory facilities at Cambridge Science Park, dedicated to its contract research services.

A screening tool developed in research led at the University of Strathclyde, UK could increase the number of tests on a solid tumor sample by up to 50 times.

MaxCyte, Inc. has announced the signing of a strategic platform license with LG Chem Ltd.

Lucius Partners, LLC has reported that its portfolio company, Voltron Therapeutics, Inc., had announced the initiation of a preclinical study of its novel vaccine candidate VTX-067 in an immune-oncology model.

On Friday 1 July, Health Data Research UK launches its Health Data Science Black Internship Programme for 2022 helping to tackle the underrepresentation of Black people within science, technology, engineering, and mathematics careers. 

Spirea Limited has announced that it has secured funding of £2.4 million with investments from high-profile UK and US investors.

SomaLogic has announced it has signed a licensing agreement with OncoHost.

CytoSMART Technologies today announced the launch of a new Organoid Analysis Module for use with its flagship CytoSMART Omni live-cell imaging product line.